This study is an extended follow-up of the study (ClinicalTrials.gov ID: NCT01758120)-Treatment of prednisone plus cyclophosphamide may be superior to treatment of prednisone alone in patients with advanced-stage IgA nephropathy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
133
Prednisone and cyclophosphamide are both administered to participants in this group.
Prednisone is administered to participants in this group.
Guangdong General Hospital
Guangzhou, Guangdong, China
the changes of kidney function or death
1. addition of 2-year-follow up to the ClinicalTrials.gov ID: NCT01758120;Time Frame:4 years and 5 years after the initiation of treatment 2. the changes of estimated glomerular filtration rate (eGFR) or a combination of reaching end-stage renal disease (ESRD) or doubling of serum Creatinine or death
Time frame: a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)
the changes of proteinuria
1. addition of 2-year-follow up to the ClinicalTrials.gov ID: NCT01758120;Time Frame:4 years and 5 years after the initiation of treatment 2. the changes of proteinuria
Time frame: a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)
Number of Participants with Adverse Events
1. addition of 2-year-follow up to the ClinicalTrials.gov ID: NCT01758120;Time Frame:4 years and 5 years after the initiation of treatment 2. Number of Participants with Adverse Events; adverse events include hair loss, vomiting, diarrhea, jaundice, leukopenia, anemia, thrombocytopenia, infections, allergic reactions and hemorrhagic cystitis.
Time frame: a total of 5 years of followup (addition of 2-year-follow up to the ClinicalTrial of NCT01758120)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.